The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (TORG1018).
 
Kaoru Kubota
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tsuneo Shimokawa
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kazuhiko Yamada
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Pfizer (Inst)
 
Hiroshi Tanaka
Honoraria - AstraZeneca; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Kazuma Kishi
Speakers' Bureau - Chugai Pharma
Research Funding - Chugai Pharma (Inst); MSD (Inst)
 
Haruhiro Saito
No Relationships to Disclose
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Yukio Hosomi
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Naoyuki Nogami
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Takeharu Yamanaka
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
 
Noriyuki Masuda
Honoraria - Chugai Pharma; Nippon Kayaku
 
Koshiro Watanabe
No Relationships to Disclose